The U.S. Food and Drug Administration told manufacturers of several GLP‑1 receptor agonists used for obesity that its post‑market review found no increased risk of suicidal ideation or behavior; the agency requested removal of the suicide warning from labeling for Eli Lilly’s Zepbound (tirzepatide) and Novo Nordisk’s Saxenda (liraglutide) and Wegovy (semaglutide). The change follows multi‑year pharmacovigilance activity and will alter safety communications and risk management for leading obesity medicines. For clinicians and safety officers, the label revision reduces a former caution taken from older anorectics and may affect prescribing decisions, monitoring protocols and payer conversations.